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Summary The search for novel antitumour drugs has reached a plateau phase. The carcinomas remain almost
as intractable as they did 40 years ago and the need for effective therapy is pressing. There is an argument that
the current pharmacopoeia is sufficient but, to be effective, the biochemical mechanisms of drug resistance
must be circumvented. In tackling the question of why certain cancer cells are resistant, the converse question
of why others are sensitive still remains to be answered fully. Asking the fundamental question of why and
how a cell dies may provide clues as to what avenues lie open for improved chemotherapy. In this review we
survey the recent literature on cell death and we argue that it is possible that the outcome of chemotherapy
may be determined by the response of the cell to the formation of the drug-target complex, and/or its
sequellae, rather than to the biochemical changes brought about by the drug alone. One of these responses,
determined by the phenotype of the cell, may be activation of a genetic programme for cell death.
How do cytotoxic drugs kill cells?
Although much is known about the primary mechanisms of
action of many anticancer agents including the location of
their cellular targets, it is not yet clear how interaction with
these targets should lead to sudden or eventual cell death.
Recently, it has been suggested that diverse anticancer drugs
may induce a mode of cell death which has characteristics of
apoptosis, a phenomenon which has been conceptualised as
"programmed' cell death (Barry et al., 1990; Dyson et al.,
1986; Eastman, 1990; Ijiri & Potten, 1983; Kaufmann, 1989;
Lorico et al., 1988; Searle et al., 1975; Yoshioka et al., 1987).
These findings strongly suggest that disparate drug-induced
lesions activate a conserved, gene-activated program for cell
death. The ability of the cancer cell to mount a 'program-
med' cell death, or not, may be an important arbiter of the
therapeutic response.
How do cells die?
Several modes of cell death have been described (Wyllie,
1987, 1988; Wyllie et al., 1980; Orrenius et al., 1989; Boobis
et al., 1989; Lockshin & Beaulaton, 1981; Potten, 1987;
Bowen & Bowen, 1990). Apoptosis, first outlined by Kerr
and colleagues (1972), is a phenomenon which is morpho-
logically defined by cell shrinkage and, notably in epithelial
cells, the isolation of a cell from its neighbours by the loss of
cell-to-cell contacts. Perhaps most characteristically, there is a
specific pattern of chromatin condensation, giving a dense
crescentic mass close to the nuclear margin (Arends et al.,
1990; Wyllie, 1980). These processes are followed by the
budding off of apoptotic bodies. Apoptotic cells express new
surface signal molecules and they are rapidly recognised by
phagocytes and engulfed so that the cell dies without inflict-
ing damage to viable neighbours (Morris et al., 1984; Duvall
et al., 1985; Savill et al., 1990). Apoptosis occurs spon-
taneously in solid tumours of various types (Wyllie, 1985;
Searle et al., 1975; Szende et al., 1989; Sarraf & Bowen, 1988;
Kyprianou et al., 1990; Kerr & Searle, 1981; Kerr & Lamb,
1984). Tumour kineticists have long realised that tumour size
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is dictated by the balance between cell gain (proliferation)
and cell loss (cell death and differentiation) (Steel, 1985). Cell
loss is sometimes considerable and apoptotic cell death is a
key player in the equation which predicts tumour size and
development. Measurement of apoptotic cells in tumours is
difficult to quantify with accuracy since their 'half life' of
histologically recognisable apoptosis is short and cell samples
are often heterogeneous.
The biochemistry of apoptosis is incompletely defined; it
appears to be triggered by a plethora of diverse noxic stimuli
when they are presented at concentrations which do not
rapidly precipitate metabolic collapse (necrosis - see below).
Additionally, apoptosis plays a pivotal role in embryogenesis
and in development (Hinchliffe, 1981; Goldman et al., 1983;
Nishikawa et al., 1989). Recent studies suggest that an eleva-
tion of cellular calcium is a central event in the activation of
a calcium-magnesium-dependent endonuclease which cleaves
DNA at regular internucleosomal sites resulting in 180 base
pair integer oligonucleosomal fragments (Cohen & Duke,
1984; McConkey et al., 1989a-c and 1990; Orrenius et al.,
1988, 1989). This fragmentation is visible as DNA 'ladders'
on agarose gels (Arends et al., 1990). The endonuclease
involved in apoptosis is inhibited by zinc. In some but not all
cases where death by apoptosis occurs, inhibition of protein
synthesis by cycloheximide prevents the appearance of these
ladders (Wyllie et al., 1984); this suggests that proteins in-
strumental to the process ofcell suicide are required, perhaps
including those which regulate calcium homeostasis. Para-
doxically, there have been reports that cycloheximide induces
apoptosis (Searle et al., 1975). In stark contrast to necrosis,
apoptosis is a thermodynamically uphill process which is
thought to be genetically modulated.
Necrosis is a thermodynamically down-hill process. Non-
physiological extremes in the external environment of the cell
(e.g. hyperthermia and hypoxia) and high concentrations of
noxic substances cause a progressive loss in membrane integ-
rity, a collapse of cellular homeostasis and a depletion of
ATP levels (Wyllie et al., 1980; Judah et al., 1965). An early
fall in ATP precedes a fatal disruption of the ionic gradients
which allow the cell to do work. The cell ruptures to spill out
degradative lysosomal enzymes which mediate an inflamma-
tory reaction in the immediate locality. This is not a process
which is genetically influenced, and it would seem to be
uncontrollable, in terms of possible drug intervention, with
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the possible exception of drugs which alter tumour vascu-
lature (Denekamp et al., 1982).
The induction of apoptosis as an antitumour strategy has
already gained credibility. Krammer's group have isolated an
antibody named anti APO-1 which is reported to induce the
regression of B lymphoblastoid tumours (Trauth et al., 1989)
and Szende et al. (1989) have used analogs of somatostatin
and leutinising hormone-releasing hormone to treat panc-
reatic and mammary carcinomas by the induction of apop-
tosis.
The induction of terminal differentiation could be viewed
as a long term commitment to death. The mature neutrophil
undergoes apoptosis and on the expression of new antigens,
is selectively phagocytosed by macrophage (Savill et al., 1989,
1990). Similarly, HL-60 myelomonocytic leukaemia cells
differentiated to granulocytes undergo apoptosis (Martin et
al., 1990). There are interesting parallels between the pro-
cesses of drug-induced apoptosis and drug-induced differ-
entiation. In glucocorticoid-induced cell death of human
CCRF-CEM lymphoblastoid cells, a period of 'precommitt-
ment' is required before apoptosis is initiated (Yuh &
Thompson, 1989). The cells require at least a 24 h exposure
to dexamethasone before the activaiton of an endonuclease
after a further 12-24h. Removal of the drug's 'stimulus'
before the precommitment period is complete does not
engage the programme of cell death. These type of 'commit-
ment' kinetics have been observed with many drugs which
stimulate the differentiation of leukaemic cells (Hickman &
Friedman, 1988). The period of precommitment for cell
death is variable amongst cell types, so that certain cells can
respond within a few hours to the apoptotic stimulus and it
would seem that in these, the mechanism for programmed
cell death is ready 'primed' for activity. For example
immature thymocytes initiate apoptosis 4 h after methylpred-
nisolone (Wyllie, 1980) and HL-60 do so 2-4 h after
etoposide (Kaufmann, 1989). A number of studies suggest
that the 'precommitment' time for apoptosis to be triggered
is related to the cycle time of some cells, as well as to their
differentiated status (Ijiri & Potten, 1983).
How do drugs induce apoptosis?
Because drugs with widely disparate modes of action as
defined by their primary targets, e.g. dihydrofolate reductase
inhibitors (Lorico et al., 1988; Kaufman, 1989), 5-fluorouracil
(Dyson et al., 1986; Yoshioka et al., 1987) topoisomerase II
poisons (Kaufman, 1989) and DNA damaging agents (Barry
et al., 1990) induce events characteristics of apoptosis, the
question arises as to how a conserved response might be
initiated. What are the sensors? What are the signals? How is
the transcription of the pertinent genes activated? And what
are the roles of these gene products?
Sensors
It is difficult to articulate how a cell 'senses' damage. Since
the agents which initiate a conserved process of programmed
cell death are disparate in their mechanism of action, the
nature of the 'damage' which is to be sensed is also some-
what debatable. Most of the antitumour drugs which initiate
apoptosis reduce proliferative potential and many disrupt
passage through the cell cycle, even if only transiently. The
inhibition of proliferative potential may be one essential
component of the initiation of drug-induced cells death: this
idea is supported by a report that the DNA double strand
breaks induced by a thymidylate synthase inhibitor could be
reversed by thymidine as well as being preventable by inhib-
itors of protein synthesis (Lorico et al., 1988). Kung et al.
(1990) have suggested that perturbations of normally inte-
grated cell cycle events presents the stimulus for the cell to
engage a programme of cell death after treatment with phase-
specific agents. Also recently, the inhibitor of topoisomerase
II, etoposide, which brings about transient G2/M phase inhi-
bition, was shown to inhibit the kinase activity of p34cC12 in
Chinese Hamster Ovary cells (Lock & Ross, 1990a,b).
Changes in the activity of specific cell cycle regulated pro-
teins, might therefore represent a common type of 'damage'
that provides the initiating event for a cascade leading to cell
death.
It has been suggested that a sustained alteration of pro-
teins might also be a conserved type of mild 'damage' which
is imposed by the wide variety of agents which induce leu-
kaemic cell differentiation (Richards et al., 1988). It was
suggested that an enzyme might become locked by a tight-
binding inhibitor into a conformation which was only nor-
mally present momentarily in the cell, for example the
cleavable complex between topoisomerase II and DNA or the
complex between dihydrofolate reductase and its ligand, and
that this type of 'damage' or imbalance, together with a
reduction of proliferative potential, triggers an adaptive re-
sponse which engaged a programme of terminal different-
iation. The hypothesis, which has temporal aspects associated
with it, has parallels with a genetically highly conserved
system of detecting damage and responding to it: the activa-
tion of the transcription of heat shock genes. Here again, a
variety of disparate stimuli, gen8rally which affect protein
conformation, activate the highly conserved heat shock re-
sponse (Morimoto et al., 1990). It has been shown that cells
are able to recognise damaged, malfolded proteins and most
interestingly, and relevant to the hypothesis above, that
abnormal amounts of normally folded proteins are able to
activate heat shock gene transcription (Anathan et al., 1986).
It was recently reported that cytotoxic prostaglandins
indtdced the synthesis of a heat shock protein, although it was
not clear whether the change in synthesis was causatively
involved in the fate of the cells (Santoro et al., 1989). The
activation of the heat shock response by damage may be a
useful paradigm for considerations of how a cell 'senses'
damage, and how it signals for the initiation of transcription,
so the heat shock response will be discussed briefly:
The response of the cell to abnormal proteins (generally
those which are malfolded) is initiated at the transcriptional
level by the activation of a transcription factor which binds
to a promoter (the heat shock element). This promotor is
downstream from a number of important signal-activated
transcriptional elements which may co-regulate its activity
(Milarski & Morimoto, 1990). The synthesis of the heat
shock proteins, under conditions of a mild stress, permits the
cell to become tolerant to further stress (Riabowol et al.,
1988). It is possible that the heat shock transcription factor
acts as a partial signal: when bound to heat shock proteins it
has been proposed that it is inactive but when the heat shock
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Figure 1 Outline of some of the events describing a cellular response to the formation of a drug-receptor complex. The initiation
of the response might be due to the drug-receptor complex itself or a limited repertoire of metabolic changes which ensue from the
formation of the drug-receptor complex, such as perturbations of the cell cycle, as reflected in changes in cell cycle control proteins.194 C. DIVE & J.A. HICKMAN
proteins become associated with aberrant proteins in the cell
it is released and presumably translocated to the nucleus to
activate the promoter (Mosser et al., 1990). The heat shock
protein may act as the 'sensor' for cell damage and elegant
expeniments to map the recognition domains of the 70 kD
heat shock protein have been published recently (Milarski &
Morimoto, 1989). Whether the damage induced by different
chemotherapeutic agents is recognised directly (the drug-
receptor complex) or as a consequence of this damage, such
as the change in cdc2 (Lock & Ross, 1990a,b) remains to be
determined.
Signals
Cell signals as targets for chemotherapy have recently attract-
ed the attention of drug-hunters (Tritton & Hickman, 1990),
and it would seem an exciting proposition to consider the
nature of the signals which initiate apoptosis as potential
drug targets rather than attempting to modulate mitogenic
signals which initiate the transition between GI and S phase
of the cell cycle, where the opportunity to affect low growth
fraction tumours must be limited. Many reports have sug-
gested that a chronic, moderate elevation of cellular calcium
is required to activate the (as yet unidentified) endonuclease
which cleaves DNA and presumably results in the classical
pattern of chromatin condensation associated with apoptotic
cell death (McConkey et al., 1989a,b; Cohen & Duke, 1984).
Moreover, in some cells apoptosis is rapidly evoked by treat-
ment with calcium inophore and is prevented by chelation of
calcium (McConkey et al., 1989b). The calcium channel
blocker flunarizine inhibited neuronal cell death after with-
drawal of nerve growth factor, but the concentration
required was greater than that required to inhibit voltage
dependent calcium channels, and its mode of action was
suggested to be intracellular, possibly by inhibition of cal-
modulin, supporting a role for calcium in the activation of
apoptosis (Rich & Hollowell, 1990). It is not obvious how a
sustained calcium rise would allow the maintenance of mem-
brane integrity, typical of an apoptotic cell, nor how this type
of calcium rise would be initiated by say the presence of
transient topoisomerase II-associated DNA double strand
breaks (Lock & Ross, 1990a,b; Kaufmann, 1989). This does
not rule out the important potential of calcium to mediate
the initiation of apoptosis but experiments where calcium is
elevated artificially by ionophores may be activating just one
arm of a complex process.
Genes
What progress has been made in the identification of genes
responsible for cell death? A beautiful picture of the involve-
ment of specific genes in 'programmed' cell death has
emerged from studies of the development of the nematode
Caenorhabditis elegans (Ellis & Horvitz, 1986; Yuan & Hor-
vitz, 1990). Here, mutations of the genes ced-3 and ced-4
prevented normal patterns of cell death associated with
development. These genes act autonomously within cells
which die by apoptosis and in concert with genes which then
result in the cleavage of their DNA (nuc 1) and the engulf-
ment of the dying cells (ced-l and ced-2). Interestingly,
Hedgecock et al. (1983) have suggested that the endonuclease
may be expressed by the engulfing cells in C. elegans. In the
rat ventral prostate which undergoes apoptosis after castra-
tion due to androgen ablation, the transcriptional cascade
c-fos, c-myc and heat shock 70K was observed under tem-
poral conditions paradoxically reminiscent of the activation
of both proliferation and differentiation (Buttyan et al.,
1988). Yuh & Thompson (1989) have presented evidence that
a fall in c-myc transcription plays a major role in the
glucocorticoid-induced cell death of CRFF-CEM cells. What
appears to be a programmed cell death associated gene,
testosterone-repressed prostatic message 2 (TRPM-2), is ex-
pressed coordinately with the onset of apoptosis of the pros-
tate driven by antiandrogens (Buttyan et al., 1989; Monpetit
et al., 1986). With the exception of the C. elegans nuclease
and engulfment genes, little is known about the precise func-
tion of apoptosis-associated genes. The existence of a genetic
programme for drug-induced cell death suggests that muta-
tions of these genes might have a profound outcome on
therapy if drugs are able to initiate this process. Further-
more, the finding that the oncogene bcl-2 provides a survival
advantage for cells in which it is expressed (Tsujimoto et al.,
1985; Williams et al., 1990; Hockenberry et al., 1990; Cotter,
1990) prevents the onset of apoptosis after the withdrawal of
IL-3 from IL-3-dependent murine haematopoietic stem cells
(Vaux et al., 1988) and protects the cells from the effects of a
variety of toxins, including methotrexate (Tsujimoto, 1989)
suggests that apoptosis may be negatively modulated by
certain genes.
Chemotherapy and cell death
Despite the uncertainty enshrouding the nature of the sen-
sors, signals and changes in gene expression which initiate
cell death, we believe that questions regarding the mechanism
of drug-induced apoptosis may provide insights into some of
the reasons for the successes and failures of chemotherapy so
far and fertile ground for new programmes of drug discovery.
If, as implied above, the primary lesion, or a common secon-
dary lesion (changes in cell cycle controlling proteins, for
example) triggers a cascade which results in apoptosis, then it
is pertinent to ask why this happens in some cells to a greater
extent than in others. For instance, cultured human pro-
myelocytic leukaemic (HL60) cells appear to be exquisitely
prepared for the initiation of apoptosis (Kaufman, 1989) - as
they are for terminal differentiation (Hickman & Friedman,
1988).
Are there cellular hierarchies which determine the propen-
sity of a cell to undergo apoptosis? In the epithelia of the
intestine and in the testis this appears to be the case. The
relative promiscuity of the apoptotic response in haemo-
poietic cells (Wyllie, 1980; Baxter et al., 1989; Smith et al.,
1989; Williams et al., 1990; Liu et al., 1989), which amplify in
numbers as they proliferate and differentiate, might be
important to prevent the inheritance of damage and its
amplification during development. Perhaps surprisingly, hae-
mopoietic stem cells are relatively inefficient at mounting the
repair of cellular damage and this lack of repair capacity may
predispose them to the alternative pathway of cell death
(Figure 1). In other cell types where division and different-
iation is not associated with a significant amplification of cell
numbers, is programmed cell death more difficult to trigger
because the cells are programmed with a greater survival
potential? If this is the case, as it seems to be in some
intestinal epithelial crypt cells (Iriji & Potten, 1983; Bennett
et al., 1984), could it be that the precise nature of the
primary target for cytotoxicity is of lesser importance in
determining the outcome of therapy than the status of the
cell with respect to its ability to engage apoptosis? What the
drug-target complex may do is to provide cellular selectivity
for the initiation of a response.
This aspect of a cellular 'reaction' to the formation of a
drug receptor complex, and/or its sequellae, could be viewed
as an 'adaptive response'. If apoptosis is viewed as one of the
adaptive response repertoires of the cell, alongside the initia-
tion of alternative pathways such as differentiation, the
induction of a drug resistance phenotype - which in certain
cases may be transient (Lazo & Basu, 1991), the induction of
mechanisms of repair, or drug-induced increases in metastatic
potential (McMillan & Hart, 1987), then not surprisingly the
outcome of drug therapy will be determined by the response
of the cell, according to its phenotype, rather than by the
nature of the primary drug-target interaction alone (see
Figure 1).
Some cells, it seems, may be harder to kill than others, no
matter how ingenious the strategy or how novel the drug or
drug target, because they have an enhanced survival poten-
tial. The existance of genes which modulate the survivalDRUG TARGET INTERACTIONS 195
potential of cells, such as bcl-2 and components of certain
DNA viruses (Gregory et al., 1991), suggest that it may be
possible to selectively influence the ability of a cell to die,
hopefully irrespective of its proliferative status and, most
importantly for the drug hunter, perhaps irrespective of the
precise locus of the stimulus for cell death - the drug-target
complex.
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